Natalie C. Holles - 22 Jun 2023 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Charles N. York II, as Attorney-in-Fact for Reporting Person
Issuer symbol
DAWN
Transactions as of
22 Jun 2023
Net transactions value
$0
Form type
4
Filing time
26 Jun 2023, 19:35:26 UTC
Previous filing
08 Mar 2023
Next filing
05 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Director Stock Option (Right to buy Common Stock) Award $0 +37,500 $0.000000 37,500 22 Jun 2023 Common Stock 37,500 $12.69 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 22, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.